Identifying methods and criteria for testing

Well-informed patients provide the most useful preference information. According to an article recently published in Value & Outcomes Spotlight, this raises questions about risk communication, educating patients and psychological variables that affect patients’ preferences. 

(Image removed) Esther W. de Bekker-Grob, PREFER methodology

There is a growing need to evaluate the efficiency of methods for collecting well-informed preferences and to determine why, when and how patient preferences are most useful for different stakeholders, say the authors of Giving patients’ preferences a voice in the medical product lifecycle: why, when and how?

PREFER spent the first year identifying methods to collect patient preferences: Information that can help guide decision-making for the Pharmaceutical Industry, Health Technology Assessment authorities, Reimbursement Agencies and Payers, as well as patients themselves.  

“We have found that stakeholders in PREFER agree that patient preferences can inform benefit-risk decision making for medical products. However, there is a lack of understanding of when and how patient preferences should be included in the medical product life cycle”, says Esther W. de Bekker-Grob (Link removed) , one of the authors.

The authors have led PREFER’s work to identify methods and criteria for testing and to fill existing knowledge gaps by describing why, when and how to include patient preferences in the medical product life cycle. The authors identify a need for further development and evaluation of methods for collecting well-informed patients’ preferences.

So far, the work has included a literature review, interviews and focus groups with patient organisations, physicians, regulators, HTA bodies, industry experts and academics to find out what their concerns, needs, desires and expectations are. PREFER is a public-private partnership with researchers and experts from Industry, HTA and Academia. Right now, the teams involved are working to make results available in publications. 

As this work comes to an end, a new team begin testing the results in a number of clinical case studies (Link removed) , looking specifically at three different patient groups: Rheumatoid Arthritis, Neuromuscular Disorders and Lung Cancer. Stay tuned for more to come!

Read the article

More PREFER publications (Link removed)

By Anna Holm

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).